Stromatt was most recently executive vice president of clinical and regulatory affairs at Cell Therapeutics (NASDAQ: CTIC | Quote | Chart | News | PowerRating) in Seattle. While there, he managed global clinical research programs for several product candidates with potential applications in the field of oncology. Before Cell Therapeutics, Stromatt was vice president of clinical research and chief medical officer at Northwest Biotherapeutics (OTCBB: NWBO).
Seattle-based Trubion is a biopharmaceutical company that is working on a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer.
FinancialWire" is a fully independent, proprietary news wire service of Investrend Information (a division of Investrend Communications, Inc.). FinancialWire" news is written by professional journalists, dedicated to pure journalistic standards. FinancialWire" does not receive or accept any compensation from any individual or subject company (or representative thereof) for its news or opinions. All FinancialWire" news is available at http://www.financialwire.net . Please address any inquiries to feedback@financialwire.net .
Free annual reports for companies mentioned in the news are available at http://investrend.ar.wilink.com/?level=279 .
http://www.financialwire.net

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index